Correlation Between Activated Clotting Time and Activated Partial Thromboplastin Time During Endovascular Treatment of Cerebral Aneurysms

被引:1
作者
Faraoni, David [1 ]
Mine, Benjamin [2 ]
Nabhan, Wael [3 ]
Nokerman, Pierre [3 ]
deryck, YVon [3 ]
Baurain, Michel [3 ]
Lubicz, Boris [2 ]
机构
[1] Univ Libre Bruxelles, CHU Brugmann, Dept Anesthesiol, Brussels, Belgium
[2] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Anesthesiol, Brussels, Belgium
[3] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Diagnost & Intervent Neuroradiol, Brussels, Belgium
来源
POINT OF CARE | 2013年 / 12卷 / 03期
关键词
activated clotting time; activated partial thromboplastin time; interventional neuroradiology; anticoagulation monitoring;
D O I
10.1097/POC.0b013e3182a1774b
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Purpose: Endovascular treatment (EVT) of intracranial aneurysms (IAs) requires continuous anticoagulation to avoid thromboembolic complications. To monitor the anticoagulation, different tests may be used, including the activated clotting time (ACT) and the activated partial thromboplastin time (APTT). The aim of this study was to compare ACT and APTT for the monitoring of anticoagulation during EVT of IAs. Methods: Patients referred for EVT of an IA were included. After induction, baseline ACT and APTT were recorded, followed by a bolus infusion of unfractionated heparin (50 UI kg(-1)). The same tests were controlled 5 minutes later with the purpose of doubling the baseline ACT value. Correlation and agreement between both tests were evaluated for the percentage of change after the bolus. Multiple linear regressions were also calculated to show confounding factors. Complications and outcomes were also recorded. Results: Forty-five patients were checked for enrollment, and 24 were included for analysis. Mean (SD) percent variation for APTT was 432.1 (75.7) and 60.6 (23.0) for ACT, with P < 0.0001. With the Bland-Altman method, value of bias (SD) is 372 ( 86), with 95% limits of agreement ranging from 203 to 540. Pearson correlation for percent variation shows r (95% confidence interval) = -0.23 (-0.58 to 0.19), with P = 0.29 and R-2 = 0.05. One hundred percent of the APTT values could be defined as excessive anticoagulation by opposition of the 8% obtained with ACT. Conclusions: This prospective observational study shows that the ACT test is not well correlated with APTT and leads to a systematic excessive coagulation during EVT of IAs.
引用
收藏
页码:123 / 126
页数:4
相关论文
共 50 条
  • [31] Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration
    Casserly, IP
    Kereiakes, DJ
    Gray, WA
    Gibson, PH
    Lauer, MA
    Reginelli, JP
    Moliterno, DJ
    THROMBOSIS RESEARCH, 2004, 113 (02) : 115 - 121
  • [32] EFFECT OF SYNTHETIC PHOSPHOLIPIDS ON THE RESPONSE OF THE ACTIVATED PARTIAL THROMBOPLASTIN TIME TO HEPARIN
    VANDENBESSELAAR, AMHP
    NEUTEBOOM, J
    BERTINA, RM
    BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (06) : 895 - 903
  • [33] Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab
    Novembrino, Cristina
    Boscolo-Anzoletti, Massimo
    Galbiati, Eleonora
    Shinohara, Sho
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [34] Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time
    Koestenberger, M
    Cvirn, G
    Gallistl, S
    Muntean, W
    BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (08) : 693 - 697
  • [35] Association between Activated Partial Thromboplastin Time and the Amount of Infused Heparin at Bone Marrow Transplantation
    Kusuda, Machiko
    Kimura, Shun-ichi
    Misaki, Yukiko
    Yoshimura, Kazuki
    Gomyo, Ayumi
    Hayakawa, Jin
    Tamaki, Masaharu
    Akahoshi, Yu
    Ugai, Tomotaka
    Kameda, Kazuaki
    Wada, Hidenori
    Ishihara, Yuko
    Kawamura, Koji
    Sakamoto, Kana
    Sato, Miki
    Terasako-Saito, Kiriko
    Kikuchi, Misato
    Nakasone, Hideki
    Kako, Shinichi
    Tanihara, Aki
    Kanda, Yoshinobu
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1367 - 1371
  • [36] Clinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening A Review of the Literature and Current Guidelines for Testing
    Levy, Jerrold H.
    Szlam, Fania
    Wolberg, Alisa S.
    Winkler, Anne
    CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) : 453 - +
  • [37] Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
    Yuan, Yao
    Li, Xinyu
    Qiu, Feng
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
  • [38] Artifactual prolongation of the activated partial thromboplastin time by amikacin or gentamicin with ellagic acid, but not silica activated reagent
    Kaneko, Yousuke
    Sugasaki, Motoki
    Okada, Naoto
    Niimi, Mako
    Yasui, Saya
    Hori, Taiki
    Aihara, Ken-ichi
    Takishita, Makoto
    Abe, Masahiro
    Nakamura, Shingen
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2022, 44 (02) : E72 - E75
  • [39] Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions
    Rao, LV
    Okorodudu, AO
    Petersen, JR
    Elghetany, MT
    CLINICA CHIMICA ACTA, 2000, 300 (1-2) : 13 - 21
  • [40] Reference ranges for prothrombin time, activated partial thromboplastin time and platelet count in llamas and alpacas
    Summerfield N.
    Baird A.N.
    Boston R.
    Comparative Clinical Pathology, 2002, 11 (4) : 256 - 261